United States
  • Europe
  • News
  • US
  • World
  • Business
  • Technology
  • Science
  • Entertainment
  • Sports
  • Health

Categories

  • Artificial intelligence
  • Arts and design
  • Books
  • Business
  • Celebrities
  • Chicago
  • Computing
  • Dallas
  • Economy
  • Entertainment
  • Entrepreneurship
  • Environment
  • Fitness
  • Fort Worth
  • Gadgets
  • Genetics
  • Golf
  • Health
  • Health care
  • Houston
  • Internet
  • Jacksonville
  • Jobs
  • Los Angeles
  • Markets
  • Medication
  • Mental health
  • MLB
  • Mobile
  • Movies
  • Music
  • NASCAR
  • NBA
  • NCAA Basketball
  • NCAA Football
  • New York
  • News
  • NFL
  • NHL
  • Nutrition
  • Personal finance
  • Philadelphia
  • Phoenix
  • Physics
  • San Antonio
  • San Diego
  • Science
  • Soccer
  • Space
  • Sports
  • Technology
  • Tennis
  • TV
  • United States
  • US
  • Virtual reality
  • Wildlife
  • WNBA
  • World
United States
  • Europe
  • News
  • US
  • World
  • Business
  • Technology
  • Science
  • Entertainment
  • Sports
  • Health

Browsing Tag

retinal diseases

4 posts
GGenetics
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Read More

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

  • October 2, 2025
Opus Genetics, Inc. RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD),…
GGenetics
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Read More

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

  • September 30, 2025
Opus Genetics, Inc. Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular…
GGenetics
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Read More

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

  • September 3, 2025
Opus Genetics, Inc. RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD)…
GGenetics
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Read More

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • July 3, 2025
Opus Genetics, Inc. RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD),…
United States
www.europesays.com